The Ebola epidemic spurred a tremendous amount of R&D in search of vaccines and treatments – and yet it was a relatively low impact global emergency compared with malaria.
There is an assumption that doctors and business don’t mix. But I believe physicians are ideally placed to bring new clinical innovations from a bright idea to a brand new product.
Open innovation is more than just the latest pharma industry buzzword. Done right, it can help overcome funding challenges and accelerate discovery across the board.
Want a lightning-fast tour of the latest issue? Take a look at our new video sneak preview.
Michael N. Liebman
In today’s highly competitive academic world, are we losing sight of the real goal of biomedical research in our rush to secure funding and embrace the latest technologies?
Making grant application processes tougher can have an unexpected and dramatic effect on the demographics of applicants. Let’s not force young investigators to fall at the first hurdle.
Robert Coffin tells the bench-to-bedside story of how the first FDA-approved oncolytic virotherapy, talimogene laherparepvec (T-VEC), was translated from a colleague’s cold sore to a potential global game changer.
Whether you are a scientist working on a new intervention or a policy-maker trying to solve major public health problems, social and cultural factors are crucial pieces of the puzzle – ignore them at your peril. Here, I explain how social science can help.
Sitting Down With… Jennifer Grandis, Professor, Department of Otolaryngology – Head and Neck Surgery, Associate Vice Chancellor – Clinical and Translational Research, University of California, San Francisco, USA.
In the pharma industry of the future, only the strongest companies will survive – and that means those with the most successful collaborations.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.